First Command Advisory Services’s Neurocrine Biosciences NBIX Stock Holding History

First Command Advisory Services’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-13	Closed	-$1.44K	–	642
2025 Q1	$1.44K	Buy	+13	New	+$1.65K	﹤0.01%	517

Other funds holding NBIX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

First Command Advisory Services's NBIX Position: Q2 2025 in Review

First Command Advisory Services sold out of Neurocrine Biosciences (NBIX) in Q2 2025, closing a stake of 13 shares — an estimated $1.44K sold.

First Command Advisory Services first reported a position in NBIX in Q1 2025 and held it in 1 quarter. The position peaked at $1.44K in Q1 2025. 585 funds tracked by Wall St. Rank hold NBIX as of Q2 2025.

First Command Advisory Services reported no remaining Neurocrine Biosciences position as of Q2 2025 after selling out during the quarter.
First Command Advisory Services sold 13 Neurocrine Biosciences shares in Q2 2025, an estimated $1.44K.
First Command Advisory Services first reported a position in Neurocrine Biosciences in Q1 2025 and held it in 1 quarter.
First Command Advisory Services's Neurocrine Biosciences position peaked at $1.44K in Q1 2025.
585 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2025.

Based on First Command Advisory Services's 13F filing for Q2 2025, filed 1 Aug 2025.